Novel combination strategies for enhancing efficacy of immune checkpoint inhibitors in the treatment of metastatic solid malignancies-Reference-Cited by-同舟云学术

Novel combination strategies for enhancing efficacy of immune checkpoint inhibitors in the treatment of metastatic solid malignancies

Published:2017-08-28 Issue:14 Volume:18 Page:1477-1490
ISSN:1465-6566
Container-title:Expert Opinion on Pharmacotherapy
language:en
Short-container-title:Expert Opinion on Pharmacotherapy

Author:

Flynn Michael J.¹,Larkin James M.G.¹

Affiliation:

1. Department of Medical Oncology, Royal Marsden Hospital, London, United Kingdom

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14656566.2017.1369956

Reference128 articles.

1. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

2. Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

3. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial

4. Nivolumab in Previously Untreated Melanoma withoutBRAFMutation

5. Schachter J, Ribas A, Long GV, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival analysis of KEYNOTE-006. [cited 2017 May 15]. Available from: http://meetinglibrary.asco.org/content/165198-176

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic Immunomodulation in Gastric Cancer;Cancers;2024-01-28

2. Effectiveness and Safety of the PD-1 Inhibitor Lenvatinib Plus Radiotherapy in Patients with HCC with Main PVTT: Real-World Data from a Tertiary Centre;Journal of Hepatocellular Carcinoma;2023-11

3. New Challenges in the Diagnosis of Kidney Damage Due to Immune Checkpoint Inhibitors Therapy: An Observational Clinical Study;Diagnostics;2023-07-28

4. Combined radiotherapy and immune checkpoint inhibition for the treatment of advanced hepatocellular carcinoma;Frontiers in Oncology;2023-07-24

5. Caracterización funcional del daño renal asociado a la inmunoterapia oncológica;FarmaJournal;2023-04-30